Clinical program broadens access to ketamine-assisted therapy for an underserved population VANCOUVER, BC, Oct. 28, 2022 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced the launch of its Ketamine for Chronic and Serious…


Previous articlePT368 – Ketamine, Group Work, and the Power of Just Being There
Next articlePsychedelic Bulletin #121: The State of Psychedelic Economy and Industry; Dispatch from Horizons New York 2022